Home/Advicenne/André Ulmann

AU

André Ulmann

Former Interim Chief Executive Officer

Therapeutic Areas

Nephrology Neurology

Advicenne Pipeline

Drug	Indication	Phase
Sibnayal® (ADV7103)	Distal Renal Tubular Acidosis (dRTA)	Approved / NDA Review
ADV7103	Cystinuria	Phase 2/3
Sibnayal® (ADV6209)	Pediatric Moderate Sedation	Approved

Leadership Team at Advicenne

Chief Executive Officer

Philippe Boucheron

Chairman of the Board of Directors

Former US Vice President, Clinical Development and Medical Affairs

View full Advicenne profile